Mirum Pharmaceuticals, Inc. (MIRM) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
2461.91
↑+30% vs avg
5yr avg: 1891.81
P/FCF
↓
94.16
↓-33% vs avg
5yr avg: 141.42
30Y Low72.3·High72.3
P/B Ratio
↑
16.42
↑+136% vs avg
5yr avg: 6.97
30Y Low2.6·High12.6
ROE
↑
-8.6%
↓+85% vs avg
5yr avg: -58.1%
30Y Low-103%·High-9%
Debt/EBITDA
151.54
+0% vs avg
5yr avg: 151.54
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MIRM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mirum Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 94.2x P/FCF, 33% below the 5-year average of 141.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.2B | $4.0B | $2.0B | $1.2B | $663M | $484M | $441M | $564M | — |
| Enterprise Value | $5.2B | $4.0B | $2.1B | $1.2B | $637M | $455M | $302M | $555M | — |
| P/E Ratio → | -219.00 | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.91 | 7.61 | 5.83 | 6.48 | 8.60 | 25.27 | — | — | — |
| P/B Ratio | 16.42 | 12.60 | 8.71 | 4.85 | 4.67 | 4.02 | 2.56 | 4.32 | — |
| P/FCF | 94.16 | 72.26 | 210.57 | — | — | — | — | — | — |
| P/OCF | 92.55 | 71.03 | 190.32 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MIRM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Mirum Pharmaceuticals, Inc.'s enterprise value stands at 2461.9x EBITDA, 30% above its 5-year average of 1891.8x. The Healthcare sector median is 14.4x, placing the stock at a 17012% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.65 | 6.12 | 6.59 | 8.26 | 23.77 | — | — | — |
| EV / EBITDA | 2461.91 | 1891.81 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 72.68 | 220.78 | — | — | — | — | — | — |
MIRM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Mirum Pharmaceuticals, Inc. earns an operating margin of -4.2%. Operating margins have expanded from -58.6% to -4.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -8.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.7% | 80.7% | 75.8% | 74.8% | 83.9% | 90.1% | — | — | — |
| Operating Margin | -4.2% | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | — | — | — |
| Net Profit Margin | -4.5% | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.6% | -8.6% | -37.1% | -83.7% | -103.5% | -57.5% | -68.3% | -87.6% | — |
| ROA | -3.1% | -3.1% | -13.4% | -32.7% | -41.9% | -31.4% | -53.3% | -52.9% | -33.4% |
| ROIC | -5.0% | -5.0% | -22.2% | -42.3% | -94.8% | -208.5% | -100.7% | -137.5% | — |
| ROCE | -3.7% | -3.7% | -15.9% | -25.8% | -48.6% | -73.1% | -58.6% | -59.8% | -5.9% |
MIRM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Mirum Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 151.5x, which is highly leveraged (4506% above the sector average of 3.3x). Net debt stands at $23M ($319M total debt minus $297M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.02 | 1.02 | 1.41 | 1.24 | 0.02 | 0.02 | 0.02 | 0.03 | — |
| Debt / EBITDA | 151.54 | 151.54 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.07 | 0.42 | 0.09 | -0.18 | -0.24 | -0.81 | -0.06 | — |
| Net Debt / EBITDA | 10.80 | 10.80 | — | — | — | — | — | — | -35.64 |
| Debt / FCF | — | 0.41 | 10.21 | — | — | — | — | — | — |
| Interest Coverage | -0.49 | -0.49 | -5.07 | -9.75 | -7.89 | -3.77 | -307.25 | — | — |
MIRM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Mirum Pharmaceuticals, Inc.'s current ratio of 2.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.45x to 2.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | 2.67 | 3.10 | 4.45 | 2.94 | 3.91 | 12.80 | 9.13 | 21.22 |
| Quick Ratio | 2.55 | 2.55 | 2.93 | 4.19 | 2.85 | 3.88 | 12.80 | 9.13 | 21.22 |
| Cash Ratio | 1.86 | 1.86 | 2.22 | 3.29 | 2.34 | 3.68 | 12.56 | 8.92 | 21.22 |
| Asset Turnover | — | 0.62 | 0.50 | 0.29 | 0.22 | 0.06 | — | — | — |
| Inventory Turnover | 4.04 | 4.04 | 3.64 | 2.11 | 2.22 | 1.26 | — | — | — |
| Days Sales Outstanding | — | 86.35 | 84.82 | 133.11 | 113.65 | 62.31 | — | — | — |
MIRM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mirum Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.1% | 1.4% | 0.5% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $50M | $48M | $41M | $34M | $30M | $25M | $23M | $23M |
Peer Comparison
Compare MIRM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MIRMYou | $5B | -219.0 | 2461.9 | 94.2 | 80.7% | -4.2% | -8.6% | -5.0% | 151.5 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See MIRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MIRM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MIRM vs ALNY
Side-by-side business, growth, and profitability comparison vs Alnylam Pharmaceuticals, Inc..
Start ComparisonMIRM — Frequently Asked Questions
Quick answers to the most common questions about buying MIRM stock.
What is Mirum Pharmaceuticals, Inc.'s P/E ratio?
Mirum Pharmaceuticals, Inc.'s current P/E ratio is -219.0x. This places it at the 50th percentile of its historical range.
What is Mirum Pharmaceuticals, Inc.'s EV/EBITDA?
Mirum Pharmaceuticals, Inc.'s current EV/EBITDA is 2461.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Mirum Pharmaceuticals, Inc.'s ROE?
Mirum Pharmaceuticals, Inc.'s return on equity (ROE) is -8.6%. The historical average is -63.7%.
Is MIRM stock overvalued?
Based on historical data, Mirum Pharmaceuticals, Inc. is trading at a P/E of -219.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Mirum Pharmaceuticals, Inc.'s profit margins?
Mirum Pharmaceuticals, Inc. has 80.7% gross margin and -4.2% operating margin.
How much debt does Mirum Pharmaceuticals, Inc. have?
Mirum Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 151.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.